OPRX · OptimizeRx Corp
5 customers — 47% of revenue (the year ended December 31, 2025)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
3 customers — 10% of revenue (2025)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
5 customers — 49% of revenue (the year ended December 31, 2024)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
2 customers — 10% of revenue (2024)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.3M | first quarter of 2026 | — |
| Average revenue per top 20 pharmaceutical manufacturers | $2,838K | FY2025 | — |
| Net revenue retention | 116% | FY2025 | — |
| Percent of total revenue attributable to top 20 pharmaceutical manufacturers | 52% | FY2025 | — |
| Revenue per average full-time employee | $839K | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OPRX
this stock
OptimizeRx Corp
|
$118.97M | -48.3% | +18.8% | 17.6 | 7.8% |
|
VEEV
Veeva Systems Inc
|
$32.68B | -9.9% | +28.1% | 35.7 | 4.9% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.41B | -10.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.05B | +93.5% | -0.4% | 51.8 | 5.1% |
|
HQY
Healthequity, Inc.
|
$8.46B | +10.5% | +28.7% | 37.9 | 6.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OPRX | -2.6% | +23.8% | -41.9% | +10.8% | -48.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.6% | +23.9% | -49.4% | +11.6% | -56.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.